Designed for diabetes but used for obesity at higher doses, the medications induce loss of 15 to 22 percent of body weight on average — more than enough to significantly reduce cardiovascular and other health risks. That makes them far superior to old-style diet pills that delivered smaller benefits along with nasty side effects such as high blood pressure and loose stools.
- October 31, 2022
Millions of U.S. adults who are overweight or obese are unable to afford the latest treatment in obesity medicine, a study by the Yale School of Medicine has found.
- October 18, 2022
Yale Endocrinology Obesity Medicine is a multidisciplinary program.
- October 17, 2022
Yale endocrinology section members presented recent findings at the European Association for the Study of Diabetes, and the American Society for Bone and Mineral Research Annual Meeting.
- October 14, 2022Source: Medscape
New insights into the benefits of treatment with the "twincretin" tirzepatide for people with overweight or obesity come from new findings reported at the annual meeting of the European Association for the Study of Diabetes.
- October 07, 2022Source: Endocrinology Network
The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) have released a new consensus report aimed at providing evidence-based recommendations as well as an overview of the benefits and challenges with automated insulin delivery (AID).
- October 06, 2022Source: American Diabetes Assocation
A new consensus report addressing the benefits, challenges, and recommendations related to automated insulin delivery (AID) is being jointly published today by two leading diabetes organizations: the American Diabetes Association® (ADA) and the European Association for the Study of Diabetes (EASD). The ADA and the EASD convened a joint Diabetes Technology Working Group to review the current landscape of AID systems and recommend targeted actions.
- October 06, 2022Source: Health and Veritas
On the Health & Veritas podcast, Yale physician-professors Howard Forman and Harlan Krumholz talk about the latest news and ideas in healthcare and seek out the truth amid the noise. In this episode, they look at the plunging cost of sequencing an individual genome, and the concussion crisis facing the National Football League. And they’re joined by Dr. Ania Jastreboff, a Yale obesity specialist, to discuss the dramatic results from a new class of drugs that target the brain’s system for regulating body fat.
- September 29, 2022Source: Health Day
A new technology dubbed the "bionic pancreas" may beat standard treatment in helping people with type 1 diabetes control their blood sugar levels, a clinical trial has found.
- September 29, 2022Source: NEJM
In January 1922, the management of type 1 diabetes was forever altered when Leonard Thompson became the first person to receive an injection of insulin extract. Although treatment with insulin therapy has been possible for more than a century, providers and persons with type 1 diabetes are faced with the grim reality that the attainment of glycemic targets remains elusive for many, increasing the risk of microvascular and macrovascular complications.